España

C.E.R.A.: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease

Francesco Locatelli
Direttore Strttura Complessa di Nefrologia e Dialisi, Azienda Ospedaliera di Lecco, Ospedale 'Allessandro Manzoni, Via Dell' Eremo 9/11, 23900 Lecco, Italy

Abstract:
C.E.R.A., a continuous erythropoietin receptor activator, has been developed for the treatment of anaemia in patients with chronic kidney disease. Compared with other erythropoiesis-stimulating agents, C.E.R.A. has a unique pharmacological profile, including a longer elimination half-life and slower clearance rate. This allows C.E.R.A. to be administered at extended intervals up to once every month. Phase III clinical trials have shown that C.E.R.A. once every 2 weeks corrects anaemia in erythropoiesis-stimulating agent-naive patients who are on or are not on dialysis, whereas once-monthly C.E.R.A. maintains stable haemoglobin levels when patients are directly converted from more frequent epoetin or darbepoetin alfa administration. C.E.R.A. is well tolerated. This review summarises clinical data on C.E.R.A. and discusses the potential effect of this novel agent on clinical practice.

    Download the full text article now - yours free of charge from AnaemiaWorld